Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England Journal of Medicine and presented at the European Congress on…
GLP-1s
A federal judge has upheld the FDA’s decision to remove Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro from the national drug shortage list, Reuters reported May 7. The ruling, issued in a sealed order by Judge Mark…
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient doses of Wegovy for $499 per month. Eligible self-paying…
Novo Nordisk said that it will begin offering its popular weight loss drug Wegovy through telehealth companies Hims & Hers, Ro and LifeMD to expand patient access, now that the medication is no longer in short supply, CNBC News reported…
Gen Alpha (children 14 and younger) led the rise of GLP-1 utilization from 2023 to 2024, with an 85% growth rate in that period. But what is behind the sharp increase? 3 factors at play There are several factors behind…
Advertisement
Medicare coverage of obesity medications could drive a substantial rise in healthcare spending, according to a new study. A microsimulation model published in JAMA Health Forum projected that Medicare expenditures would increase by $47.7 billion over 10 years if drugs…
Eli Lilly announced plans to manufacture its new weight loss pill, orforglipron, in the U.S., with global distribution set to begin in 2026, Bloomberg reported April 18. The move comes as President Donald Trump presses companies to shift to domestic…
As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal policy In early April, CMS rejected a Biden-era…
Eli Lilly completed a phase 3 trial for its weight loss drug, orforglipron, which showed promising results in evaluating its safety and efficacy for adults with Type 2 diabetes and inadequate glycemic control. The once-daily oral GLP-1 receptor agonist significantly…
At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of Internal Medicine. Researchers at Mass…